RxDoctor Payments Data

Christopher English, MD

Cardiovascular Disease · Nashville, TNNPI 1518161009

Payments from drug & device makers

$2,374in general payments, 2019–2025

Across 96 payments — averaging $24.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$821
  • Amgen$732
  • Boehringer Ingelheim$371
  • Esperion Therapeutics, Inc.$115
  • Novartis$112
  • E.r. Squibb & Sons, L.L.C.$104
  • plus $118 from 4 others

What the payments were for

  • Food & beverage$2,374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,374 in reported general payments places this provider in the 50th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$230,836
Medicare patients
1,308
Services billed
3,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban479$695,033
EntrestoSacubitril/Valsartan144$221,984
XareltoRivaroxaban100$139,576
Repatha SureclickEvolocumab159$136,217
JardianceEmpagliflozin27$46,758
FarxigaDapagliflozin Propanediol23$39,248
Praluent PenAlirocumab43$32,576
BrilintaTicagrelor28$31,555
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,124
Repatha PushtronexEvolocumab11$11,074
Ranolazine ErRanolazine43$10,374
Atorvastatin Calcium347$4,232
Metoprolol Succinate181$3,210
Losartan Potassium277$3,198
Flecainide Acetate64$3,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$695,033479 claims
NovartisEntresto$112$221,984144 claims
Johnson & JohnsonXarelto$55$139,576100 claims
Boehringer IngelheimJardiance$371$46,75827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →